MedTrace Logo

Specific Molecular Signatures Predict Neoadjuvant Chemotherapy Response in Cervical Cancer

NCT03229187 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2020-06-16

No results posted yet for this study

Summary

Cervical cancer is one of the major health problems for chinese women. Besides surgery and radiotherapy, neoadjuvant chemotherapy has been proved to be an effective program by many studies.

However, not all patients respond well to neoadjuvant chemotherapy. Knowing the therapeutic effect of the neoadjuvant chemotherapy before receiving it can not only reduce the economic burden, but also more importantly save time to take more suitable treatments.

This study is undertaken to build specific molecular signatures to predict the effects of neoadjuvant chemotherapy.

Conditions

Sponsors & Collaborators

  • Huazhong University of Science and Technology

    lead OTHER

  • Zhejiang University

    collaborator OTHER

  • Wuhan Central Hospital

    collaborator OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03229187 on ClinicalTrials.gov